Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study

Psychopharmacology

Volumn 233, Issue 14, 2016, Pages 2663-2674

  Kinoshita, Toshihiko ^a   Bai, Ya Mei ^b,c   Kim, Jong Hoon ^d   Miyake, Mutsuo ^e   Oshima, Nobuyuki ^e  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Gachon University   (South Korea)

^e Merck Sharp Dohm Res Labs Japan   (Japan)

Author keywords

Asenapine; Efficacy; Schizophrenia; Tolerability

Indexed keywords

ASENAPINE; PLACEBO; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TAIWAN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SAFETY; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REPUBLIC OF KOREA; SAFETY; SCHIZOPHRENIA; TAIWAN; TREATMENT OUTCOME;

EID: 84976421815     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4295-9     Document Type: Article

References (23)

1. Abi-Dargham A (2014) Schizophrenia: overview and dopamine dysfunction. J Clin Psychiatry 75:e31
2. American Psychiatric Association (2000) Diagnostic and Stastical Manual of Mental Disorders: DSM-IV-TR. Washington, DC.
3. Citrome L (2014a) Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 10:893–903
4. Citrome L (2014b) Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf 13:803–830
5. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU (2012) Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26:733–759
6. Merck Sharp & Dohme B.V. (2014) Saphris (asenapine) sublingual tablets. Prescribing information, revised November 2014. Available from: http://pi.actavis.com/data_stream.asp?product_group=1908&p=pi&language=E. Accessed 28 Feb 2015
7. Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86:84–91
8. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Department of HEW Publication, Washington, DC
9. Inada T (2009) A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyrammidal Symptoms Scale
10. Kane JM (2011) Addressing side effects from antipsychotic treatment in schizophrenia. J Clin Psychiatry 72:e07
11. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J (2010) Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 30:106–115
12. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
13. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223
14. Lublin H, Eberhard J, Levander S (2005) Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20:183–198
15. Minassian A, Young J (2010) Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother 11:2107–2115
16. Pompili M, Serafini G, Innamorati M, Ambrosi E, Telesforo L, Venturini P, Giordano G, Battuello M, Lester D, Girardi P (2011) Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? Expert Rev Neurother 11:989–1006
17. Potkin SG, Cohen M, Panagides J (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 68:1492–1500
18. Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65–73
19. Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H (2012) Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry 73:1533–1540
20. Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 110:1–23
21. Tandon R, Nasrallah HA, Keshavan MS (2010) Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res 122:1–23
22. Tarazi FI, Neill JC (2013) The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov 8:93–103
23. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645